Latest revenue
$2.4M
as of 2026-03-31
Latest net income
$-4.5M
as of 2026-03-31
Net margin
-189.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.8M
- Enterprise value
- $2.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $25.95
- 52-wk low
- $0.19
- Beta
- —
- Shares out
- 2.7M
5-year trend
What this company does
Business Overview Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the “Aquadex System”). The Aquadex SmartFlow® system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. Please note that selected authors…
AI summary unavailable — showing raw filing excerpt
Generated from NUWE's filing dated 2026-03-11
Key risks
Risk Factors. Our business faces many risks. We believe the risks described below are the material risks we face. However, the risks described below may not be the only risks we face. Additional unknown risks or risks that we currently consider immaterial may also impair our business operations. If any of the events or circumstances described below actually occurs, our business, financial condition or results of operations could suffer, and the trading price of our shares of common stock could decline significantly. Investors should consider the specific risk factors discussed below, together with the “Cautionary Note Regarding Forward-Looking Statements” and the other information contained…
AI summary unavailable — showing raw filing excerpt
Generated from NUWE's filing dated 2026-03-11
Profitability
Gross margin
62.0%
4.6%Operating margin
-134.3%
6.8%Net margin
-211.9%
65.8%Return on equity
-667.7%
290.4%Return on assets
-286.4%
153.0%Leverage
Debt / equity
1.33×
160.6%Long-term debt / equity
0.00×
100.0%Debt / assets
57.1%
68.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $2.4M | +26.2% | $-4.5M | -50.7% | -189.0% |
Q4 2025 2025-12-31 | $2.4M | +4.4% | $-2.4M | -65.0% | -99.9% |
Q3 2025 2025-09-30 | $2.2M | -6.3% | $468.0K | -80.2% | 21.1% |
Q2 2025 2025-06-30 | $1.7M | -21.4% | $-12.6M | -62.5% | -727.7% |
Q1 2025 2025-03-31 | $1.9M | +2.5% | $-3.0M | +30.4% | -158.3% |
Q4 2024 2024-12-31 | $2.3M | — | $-1.5M | — | -63.2% |
Q3 2024 2024-09-30 | $2.4M | -1.9% | $2.4M | +170.0% | 99.6% |
Q2 2024 2024-06-30 | $2.2M | +5.7% | $-7.7M | -59.4% | -352.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Electromedical & Electrotherapeutic Apparatus · SIC 3845
Your notes
Keep private notes on NUWE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns NUWE
Institutional value
$5.5K
Total shares held
5.2K
Distinct holders
4
-5 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | CITIGROUP INC | 5.1K | $5.4K | +5.1K (+170766.7%) | Added |
| 2 | SBI Securities Co., Ltd. | 63 | $66 | +0 (+0.0%) | No change |
| 3 | UBS Group AG | 46 | $48 | -532 (-92.0%) | Trimmed |
| 4 | Caitong International Asset Management Co., Ltd | 4 | $4 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once NUWE's latest filing finishes processing.